Form 8-K - Current report:
SEC Accession No. 0001640334-24-001541
Filing Date
2024-10-18
Accepted
2024-10-18 16:42:31
Documents
15
Period of Report
2024-10-16
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

Document Format Files

Seq Description Document Type Size
1 FORM 8-K lxrp_8k.htm   iXBRL 8-K 24420
  Complete submission text file 0001640334-24-001541.txt   163689

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lxrp-20241016.xsd EX-101.SCH 6120
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lxrp-20241016_lab.xml EX-101.LAB 16209
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE lxrp-20241016_cal.xml EX-101.CAL 898
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lxrp-20241016_pre.xml EX-101.PRE 11893
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE lxrp-20241016_def.xml EX-101.DEF 4149
17 EXTRACTED XBRL INSTANCE DOCUMENT lxrp_8k_htm.xml XML 5583
Mailing Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7
Business Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7 250-765-6424
Lexaria Bioscience Corp. (Filer) CIK: 0001348362 (see all company filings)

EIN.: 202000871 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 8-K | Act: 34 | File No.: 001-39874 | Film No.: 241381184
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)